Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03466736 · ClinicalTrials.gov registry record
Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects
A clinical trial of Alzheimer Disease and Mild Cognitive Impairment, sponsored by University of Utah.
- Completed
- Registry status
- 165
- Enrollment target
- 1
- Study location
NCT03466736 is a study of Alzheimer Disease and Mild Cognitive Impairment that has completed, run by University of Utah. The registered enrollment target is 165 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03466736, a study of Alzheimer Disease and Mild Cognitive Impairment, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- 165 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to demonstrate that individuals with low short-term practice effects (STPE) on cognitive testing are more likely to be identified as "positive" on amyloid imaging than individuals with high STPE. STPE may also inform us about other AD-related biomarkers, including hippocampal volumes, functional connectivity, and APOE status. By realizing the aims of this pragmatic study, we hope to be able to offer more economical and efficient screening of potential participants for clinical trials, which would reduce participant burden and financial costs.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST [18F]flutemetamol PET scan
Study Locations (1)
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2018-09-01 |
| Est. Completion | 2023-04-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03466736
The ClinicalTrials.gov registry entry for NCT03466736 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (94% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which [18F]flutemetamol PET scan is the first listed.
NCT03466736 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT03466736 about?
NCT03466736 is a clinical study titled "Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects". The primary objective of this study is to demonstrate that individuals with low short-term practice effects (STPE) on cognitive testing are more likely to be identified as "positive" on amyloid imaging than individuals with high STPE. STPE may also inform us about other AD-related biomarkers, includ...
What is the current status of trial NCT03466736?
This trial is currently completed. The enrollment target is 165 participants. The study started on 2018-09-01. Estimated completion is 2023-04-20.
What conditions does trial NCT03466736 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment.
What interventions are being tested in trial NCT03466736?
The interventions under investigation include: [18F]flutemetamol PET scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03466736?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03466736 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.